Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2004

View Archived Issues

Update on the antitumor efficacy of MDX-010

Durect and NeuroSystec enter development agreement for inner ear disorders

Senetek licenses Invicorp to Ardana for Europe

Phase II ramoplanin trial in C. difficile-associated diarrhea completes enrollment

NovaDel Pharma submits NDA for aerosol nitroglycerin lingual spray

Safety issues associated with Pivanex plus docetaxel in phase IIb study

Mechanisms of femoral fracture healing in rats by TP-508

Sustained clinical response achieved with abatacept in rheumatoid arthritis

CuraGen and Seattle Genetics sign ADC technology agreement

Schering-Plough licenses garenoxacin rights from Toyama

Merck & Co. and Vertex collaborate on development of VX-680

Synthetic adrenal steroid hormones protect from chemotherapy or radiation-induced myelodepression

Novel synthetic glycolipid promising against hepatitis B and C viruses

Characterization of a novel noncompetitive antagonist of GluK5 receptors

Antiischemic nitric oxide donor effective against thrombosis in vivo

Merger of CellExSys and Chromos Molecular Systems

Merck & Co. and NitroMed collaborative COX-2 inhibitor enters phase II

Positive interim results from phase II trial of FK-228 in CTCL and PTCL

Merix Bioscience and Kirin Brewery collaborate on dendritic cell vaccines

New phase II study of talabostat in CLL

Merck scientists present more GABA-A receptor ligands for anxiety and other uses

New IP receptor antagonists and their use in urological disorders claimed by Bayer

New HNE inhibitors and their use covered by AstraZeneca patent

Theravance presents new muscarinic M2 antagonists with utility in overactive bladder

Dual dopamine D2/5-HT2A antagonists identified by Pfizer scientists

Vertex claims new inhibitors of ROCK and other kinases

New antiangiogenic agents in early development at Bayer

Preclinical studies on possible effects of anti-human Fas antibody R-125224 in autoimmune diseases

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...